G. Arbour

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial.

A. Mestrovic, N. Chng, S. Tyldesley, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Progression-free survival and local control following stereotactic ablative radiotherapy for up to 5 oligometastases: an analysis from the population-based phase II SABR-5 trial.

N. Chng, S. Tyldesley, Mengxing Liu, 2022, International journal of radiation oncology, biology, physics.